import type { CompetitorRecord } from './competitor-database';

export const SPECIALTY_COMPETITORS_1: CompetitorRecord[] = [
  // ─── HIV/AIDS ───────────────────────────────────────────────────────────────
  {
    asset_name: 'Biktarvy',
    generic_name: 'bictegravir/emtricitabine/tenofovir alafenamide',
    company: 'Gilead Sciences',
    indication: 'HIV/AIDS',
    indication_specifics: 'Complete single-tablet regimen for HIV-1 infection in treatment-naive and virologically suppressed adults',
    mechanism: 'Integrase strand transfer inhibitor + dual NRTI backbone',
    mechanism_category: 'integrase_inhibitor',
    molecular_target: 'HIV integrase, reverse transcriptase',
    phase: 'Approved',
    primary_endpoint: 'Virologic suppression (HIV-1 RNA <50 copies/mL) at week 48',
    key_data: 'Non-inferior to dolutegravir-based regimens in Phase 3 trials with >99% virologic suppression at 48 weeks; zero cases of treatment-emergent resistance through 7 years of data',
    line_of_therapy: '1L and switch',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Highest barrier to resistance among single-tablet regimens with zero treatment-emergent resistance observed',
      'Once-daily single-tablet regimen with excellent tolerability and minimal drug interactions',
      'Dominant market share (~45% of new HIV starts in the US)',
    ],
    weaknesses: [
      'Patent expiration approaching with generic competition expected in late 2030s',
      'Premium pricing limits access in low- and middle-income countries',
      'Renal and bone safety considerations inherited from TAF backbone in elderly patients',
    ],
    source: 'Gilead Sciences 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cabenuva',
    generic_name: 'cabotegravir + rilpivirine',
    company: 'ViiV Healthcare/Johnson & Johnson',
    indication: 'HIV/AIDS',
    indication_specifics: 'Long-acting injectable regimen for virologically suppressed adults switching from oral antiretrovirals',
    mechanism: 'Integrase strand transfer inhibitor + non-nucleoside reverse transcriptase inhibitor (long-acting injectable)',
    mechanism_category: 'integrase_inhibitor',
    molecular_target: 'HIV integrase, reverse transcriptase (NNRTI site)',
    phase: 'Approved',
    primary_endpoint: 'Non-inferiority in maintaining virologic suppression vs. continued oral ART at week 48',
    key_data: 'ATLAS-2M demonstrated every-2-month dosing was non-inferior to monthly dosing with 94.3% virologic suppression; first long-acting complete HIV regimen',
    line_of_therapy: 'Switch (virologically suppressed)',
    partner: 'Johnson & Johnson',
    nct_ids: ['NCT03299049', 'NCT02938520'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First and only long-acting injectable HIV regimen enabling every-2-month dosing',
      'Eliminates daily pill burden improving adherence and reducing stigma',
      'High patient satisfaction scores in clinical trials (>97% preferred injections over daily pills)',
    ],
    weaknesses: [
      'Requires healthcare facility visits for intramuscular injection administration',
      'Risk of rilpivirine resistance mutations upon virologic failure limiting subsequent treatment options',
      'Not indicated for treatment-naive patients or those with prior NNRTI resistance',
    ],
    source: 'ViiV Healthcare 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lenacapavir',
    generic_name: 'lenacapavir',
    company: 'Gilead Sciences',
    indication: 'HIV/AIDS',
    indication_specifics: 'Twice-yearly subcutaneous injection for multidrug-resistant HIV-1 and as PrEP',
    mechanism: 'First-in-class HIV capsid inhibitor disrupting multiple stages of viral replication',
    mechanism_category: 'capsid_inhibitor',
    molecular_target: 'HIV-1 capsid protein (CA)',
    phase: 'Approved',
    primary_endpoint: 'Virologic suppression at week 52 in heavily treatment-experienced patients (CAPELLA); HIV incidence reduction for PrEP (PURPOSE)',
    key_data: 'CAPELLA: 73% of heavily treatment-experienced patients achieved virologic suppression; PURPOSE 1: zero HIV infections in women receiving lenacapavir vs. background incidence of 2.41/100 person-years',
    line_of_therapy: 'Salvage therapy and PrEP',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class capsid inhibitor with a novel mechanism active against multidrug-resistant HIV',
      'Twice-yearly dosing represents the longest-acting HIV therapeutic available',
      'Demonstrated 100% efficacy in HIV prevention in the PURPOSE 1 PrEP trial',
    ],
    weaknesses: [
      'Injection site reactions reported in a significant minority of patients',
      'Complex manufacturing and high cost limit global accessibility',
      'Limited long-term safety data given recent approval',
    ],
    source: 'Gilead Sciences 2024',
    last_updated: '2025-01-15',
  },

  // ─── Respiratory Syncytial Virus ────────────────────────────────────────────
  {
    asset_name: 'Beyfortus',
    generic_name: 'nirsevimab',
    company: 'Sanofi/AstraZeneca',
    indication: 'Respiratory Syncytial Virus',
    indication_specifics: 'Prevention of RSV lower respiratory tract disease in neonates and infants during their first RSV season',
    mechanism: 'Long-acting monoclonal antibody targeting RSV F protein prefusion conformation',
    mechanism_category: 'anti_rsv_mab',
    molecular_target: 'RSV fusion (F) protein',
    phase: 'Approved',
    primary_endpoint: 'Incidence of medically attended RSV-associated lower respiratory tract infection through 150 days',
    key_data: 'MELODY trial: 74.5% reduction in medically attended RSV LRTI; single intramuscular dose provides protection for entire RSV season with extended half-life (~70 days)',
    line_of_therapy: 'Prevention',
    partner: 'AstraZeneca',
    nct_ids: ['NCT03979313'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Single-dose passive immunization protecting all infants regardless of gestational age',
      'Extended half-life engineered antibody providing season-long protection',
      'Replaces the monthly palivizumab dosing paradigm with a single injection',
    ],
    weaknesses: [
      'Supply constraints during initial launch seasons limited uptake',
      'Does not induce active immunity so protection wanes after one season',
      'High per-dose cost relative to maternal vaccination alternatives',
    ],
    source: 'Sanofi 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Abrysvo',
    generic_name: 'RSVpreF (bivalent)',
    company: 'Pfizer',
    indication: 'Respiratory Syncytial Virus',
    indication_specifics: 'Prevention of RSV-associated lower respiratory tract disease in infants via maternal vaccination and in adults aged 60+',
    mechanism: 'Bivalent prefusion F protein-based vaccine (RSV-A and RSV-B)',
    mechanism_category: 'rsv_vaccine',
    molecular_target: 'RSV prefusion F protein (subgroups A and B)',
    phase: 'Approved',
    primary_endpoint: 'Efficacy against medically attended severe RSV LRTI in infants (maternal) and symptomatic RSV LRTD in older adults',
    key_data: 'MATISSE maternal trial: 81.8% efficacy against severe RSV LRTI in infants through 90 days; RENOIR adult trial: 66.7% efficacy against RSV LRTD with 2+ symptoms in adults 60+',
    line_of_therapy: 'Prevention',
    nct_ids: ['NCT04424316', 'NCT05035212'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Dual indication covering both maternal immunization and older adults',
      'Bivalent formulation provides broad coverage against RSV-A and RSV-B strains',
      'Active immunization approach that may confer longer-duration protection than passive antibodies',
    ],
    weaknesses: [
      'Maternal vaccination requires precise timing during pregnancy (32-36 weeks gestation)',
      'FDA flagged potential preterm birth signal requiring ongoing pharmacovigilance',
      'Efficacy wanes significantly beyond 6 months post-vaccination in the elderly',
    ],
    source: 'Pfizer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Arexvy',
    generic_name: 'RSVPreF3 (adjuvanted)',
    company: 'GSK',
    indication: 'Respiratory Syncytial Virus',
    indication_specifics: 'Prevention of RSV-associated lower respiratory tract disease in adults aged 60 and older',
    mechanism: 'Adjuvanted recombinant RSV prefusion F protein vaccine (subgroup A)',
    mechanism_category: 'rsv_vaccine',
    molecular_target: 'RSV prefusion F protein (subgroup A)',
    phase: 'Approved',
    primary_endpoint: 'Vaccine efficacy against RSV-associated LRTD in adults aged 60+',
    key_data: 'AReSVi-006 trial: 82.6% efficacy against RSV LRTD and 94.1% efficacy against severe RSV LRTD in the first season; AS01E adjuvant enhances immune response',
    line_of_therapy: 'Prevention',
    nct_ids: ['NCT04886596'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First approved RSV vaccine for older adults with robust efficacy exceeding 80%',
      'AS01E adjuvant system amplifies immune response particularly in immunosenescent elderly',
      'Strong efficacy against severe disease (>94%) reduces hospitalizations',
    ],
    weaknesses: [
      'Approved only for adults 60+, no maternal or pediatric indication',
      'Monovalent design targeting RSV-A prefusion F may have reduced RSV-B coverage',
      'Reactogenicity profile (fatigue, myalgia, headache) may limit uptake in vaccine-hesitant populations',
    ],
    source: 'GSK 2024',
    last_updated: '2025-01-15',
  },

  // ─── Influenza ──────────────────────────────────────────────────────────────
  {
    asset_name: 'Xofluza',
    generic_name: 'baloxavir marboxil',
    company: 'Roche',
    indication: 'Influenza',
    indication_specifics: 'Treatment of acute uncomplicated influenza and post-exposure prophylaxis in patients 1 year and older',
    mechanism: 'Cap-dependent endonuclease inhibitor blocking viral mRNA transcription initiation',
    mechanism_category: 'cap_endonuclease_inhibitor',
    molecular_target: 'Influenza polymerase acidic (PA) protein endonuclease domain',
    phase: 'Approved',
    primary_endpoint: 'Time to alleviation of influenza symptoms',
    key_data: 'CAPSTONE-1: single-dose baloxavir reduced time to symptom alleviation by ~27 hours vs. placebo; more rapid reduction in viral load compared to oseltamivir at 24 hours',
    line_of_therapy: '1L acute treatment',
    nct_ids: ['NCT02954354'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Single-dose oral treatment offers significant convenience advantage over 5-day oseltamivir course',
      'Novel mechanism of action provides alternative for neuraminidase inhibitor-resistant strains',
      'Rapid viral load reduction superior to oseltamivir at 24 hours post-treatment',
    ],
    weaknesses: [
      'PA/I38T resistance substitution detected in ~10% of treated patients reducing susceptibility',
      'Premium pricing relative to generic oseltamivir limits widespread use',
      'Clinical symptom improvement is modest compared to the virologic benefit',
    ],
    source: 'Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tamiflu',
    generic_name: 'oseltamivir phosphate',
    company: 'Roche',
    indication: 'Influenza',
    indication_specifics: 'Treatment of acute uncomplicated influenza A and B in patients 2 weeks and older; prophylaxis in patients 1 year and older',
    mechanism: 'Neuraminidase inhibitor preventing viral release from host cells',
    mechanism_category: 'neuraminidase_inhibitor',
    molecular_target: 'Influenza neuraminidase (NA) enzyme',
    phase: 'Approved',
    primary_endpoint: 'Time to alleviation of influenza symptoms',
    key_data: 'Meta-analysis of RCTs: reduces symptom duration by ~1 day when initiated within 48 hours; reduces hospitalization risk by ~25% in high-risk patients; widely available as generic',
    line_of_therapy: '1L acute treatment and prophylaxis',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Decades of clinical experience and well-characterized safety profile across all age groups',
      'Generic availability ensures broad accessibility and low cost',
      'Approved for both treatment and prophylaxis with pediatric formulations available',
    ],
    weaknesses: [
      'Five-day twice-daily dosing regimen reduces convenience and adherence',
      'Modest clinical benefit (~1 day symptom reduction) questioned by some meta-analyses',
      'Increasing prevalence of NA resistance mutations (H275Y) in circulating strains',
    ],
    source: 'Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Pimodivir',
    generic_name: 'pimodivir',
    company: 'Johnson & Johnson',
    indication: 'Influenza',
    indication_specifics: 'Treatment of acute uncomplicated influenza A in hospitalized patients and high-risk outpatients',
    mechanism: 'PB2 cap-binding domain inhibitor blocking viral mRNA cap-snatching',
    mechanism_category: 'pb2_inhibitor',
    molecular_target: 'Influenza PB2 polymerase subunit cap-binding domain',
    phase: 'Phase 3',
    primary_endpoint: 'Time to sustained clinical response in hospitalized influenza A patients',
    key_data: 'Phase 2b TOPAZ trial: combination with oseltamivir showed accelerated viral load decline versus oseltamivir alone; Phase 3 program in hospitalized patients',
    line_of_therapy: 'Combination with standard of care',
    nct_ids: ['NCT03376321', 'NCT03381196'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Novel mechanism targeting PB2 is complementary to neuraminidase and endonuclease inhibitors',
      'Designed for combination therapy to address hospitalized severe influenza unmet need',
      'Active against oseltamivir-resistant influenza A strains',
    ],
    weaknesses: [
      'Active only against influenza A, providing no coverage for influenza B infections',
      'Phase 3 PANORAMIC trial was discontinued, raising questions about clinical development path',
      'Resistance mutations in PB2 domain can emerge during treatment',
    ],
    source: 'Johnson & Johnson 2024',
    last_updated: '2025-01-15',
  },

  // ─── MRSA Infections ───────────────────────────────────────────────────────
  {
    asset_name: 'Zyvox',
    generic_name: 'linezolid',
    company: 'Pfizer',
    indication: 'MRSA Infections',
    indication_specifics: 'Treatment of nosocomial and community-acquired MRSA pneumonia, complicated skin and soft tissue infections, and vancomycin-resistant Enterococcus infections',
    mechanism: 'Oxazolidinone antibiotic inhibiting bacterial protein synthesis at the 50S ribosomal initiation complex',
    mechanism_category: 'oxazolidinone',
    molecular_target: '23S rRNA of the 50S ribosomal subunit',
    phase: 'Approved',
    primary_endpoint: 'Clinical cure rate at test-of-cure visit',
    key_data: 'Demonstrated non-inferiority to vancomycin in MRSA nosocomial pneumonia with better lung penetration; oral bioavailability near 100% enabling IV-to-oral switch; now available as generic',
    line_of_therapy: '1L and 2L for MRSA',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Excellent oral bioavailability (~100%) enabling seamless IV-to-oral step-down therapy',
      'Broad availability as generic formulation with well-established clinical use',
      'Active against vancomycin-resistant Enterococcus and most MRSA strains',
    ],
    weaknesses: [
      'Myelosuppression risk (thrombocytopenia) limits duration of therapy beyond 14 days',
      'Serotonergic drug interactions (MAOIs) require careful medication review',
      'Emerging linezolid-resistant MRSA and VRE isolates reported globally',
    ],
    source: 'Pfizer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Sivextro',
    generic_name: 'tedizolid phosphate',
    company: 'Merck',
    indication: 'MRSA Infections',
    indication_specifics: 'Treatment of acute bacterial skin and skin structure infections including those caused by MRSA',
    mechanism: 'Next-generation oxazolidinone with enhanced ribosomal binding and potency',
    mechanism_category: 'oxazolidinone',
    molecular_target: '23S rRNA of the 50S ribosomal subunit',
    phase: 'Approved',
    primary_endpoint: 'Early clinical response (>=20% reduction in lesion size at 48-72 hours)',
    key_data: 'ESTABLISH-1 and ESTABLISH-2 trials: 6-day once-daily tedizolid was non-inferior to 10-day twice-daily linezolid; lower rates of thrombocytopenia and GI adverse events vs. linezolid',
    line_of_therapy: '1L for ABSSSI',
    nct_ids: ['NCT01170221', 'NCT01421511'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Shorter 6-day once-daily course improves convenience and adherence vs. linezolid',
      'Improved safety profile with significantly lower thrombocytopenia rates',
      'Retains activity against some linezolid-resistant strains carrying cfr gene',
    ],
    weaknesses: [
      'Approved only for ABSSSI, lacking pneumonia and bacteremia indications',
      'Branded pricing significantly higher than generic linezolid',
      'Limited clinical data in severe or complicated deep-seated MRSA infections',
    ],
    source: 'Merck 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Dalbavancin',
    generic_name: 'dalbavancin',
    company: 'AbbVie',
    indication: 'MRSA Infections',
    indication_specifics: 'Treatment of acute bacterial skin and skin structure infections caused by Gram-positive organisms including MRSA',
    mechanism: 'Lipoglycopeptide antibiotic inhibiting cell wall synthesis by binding to D-Ala-D-Ala terminus of peptidoglycan precursors',
    mechanism_category: 'lipoglycopeptide',
    molecular_target: 'D-Ala-D-Ala terminus of peptidoglycan precursor (lipid II)',
    phase: 'Approved',
    primary_endpoint: 'Early clinical response (>=20% reduction in lesion size at 48-72 hours)',
    key_data: 'DISCOVER-1 and DISCOVER-2 trials: single 1500mg IV dose non-inferior to twice-daily vancomycin for 14 days; ultra-long half-life (~14.4 days) enables once-weekly or single-dose therapy',
    line_of_therapy: '1L for ABSSSI',
    nct_ids: ['NCT01339091', 'NCT01431326'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Ultra-long half-life enabling single-dose IV administration eliminates need for prolonged infusions',
      'Facilitates outpatient parenteral therapy and reduces hospital stays',
      'Potent activity against MRSA and other Gram-positive pathogens with low resistance potential',
    ],
    weaknesses: [
      'IV-only administration limits use to healthcare settings',
      'High acquisition cost per dose despite reducing downstream healthcare utilization',
      'Limited Gram-negative coverage restricts use in polymicrobial infections',
    ],
    source: 'AbbVie 2024',
    last_updated: '2025-01-15',
  },

  // ─── Clostridioides difficile Infection ─────────────────────────────────────
  {
    asset_name: 'Zinplava',
    generic_name: 'bezlotoxumab',
    company: 'Merck',
    indication: 'Clostridioides difficile Infection',
    indication_specifics: 'Reduction of recurrence of C. difficile infection in adults receiving antibacterial treatment for CDI who are at high risk for recurrence',
    mechanism: 'Human monoclonal antibody that neutralizes C. difficile toxin B',
    mechanism_category: 'anti_toxin_b_antibody',
    molecular_target: 'C. difficile toxin B',
    phase: 'Approved',
    primary_endpoint: 'Recurrence of CDI through 12 weeks after infusion',
    key_data: 'MODIFY I/II trials: bezlotoxumab reduced CDI recurrence to 17.4% vs. 27.6% for placebo (absolute reduction ~10%); particularly effective in patients with prior CDI episodes',
    line_of_therapy: 'Adjunctive to antibiotic therapy',
    nct_ids: ['NCT01241552', 'NCT01513239'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class anti-toxin approach specifically targeting CDI recurrence pathophysiology',
      'Single IV infusion provides sustained protection through the high-risk recurrence window',
      'Compatible with all standard CDI antibiotics (vancomycin, fidaxomicin, metronidazole)',
    ],
    weaknesses: [
      'Does not treat active CDI; must be used adjunctively with standard antibiotics',
      'Moderate absolute reduction in recurrence (~10%) may not justify cost for lower-risk patients',
      'Heart failure exacerbation was observed at higher rates, requiring caution in cardiac patients',
    ],
    source: 'Merck 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Vowst',
    generic_name: 'fecal microbiota spores, live-BRPK',
    company: 'Seres Therapeutics/Nestle Health Science',
    indication: 'Clostridioides difficile Infection',
    indication_specifics: 'Prevention of recurrence of CDI in adults following antibacterial treatment for recurrent CDI',
    mechanism: 'Oral microbiome therapeutic containing purified Firmicutes spores to restore colonization resistance',
    mechanism_category: 'microbiome_therapy',
    molecular_target: 'Gut microbiome composition (Firmicutes restoration)',
    phase: 'Approved',
    primary_endpoint: 'CDI recurrence through 8 weeks after treatment',
    key_data: 'ECOSPOR III trial: 12.4% recurrence rate with Vowst vs. 39.8% with placebo through 8 weeks; first orally administered microbiome therapeutic approved by FDA',
    line_of_therapy: 'Post-antibiotic recurrence prevention',
    partner: 'Nestle Health Science',
    nct_ids: ['NCT03183128'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First FDA-approved orally administered microbiota-based therapeutic for CDI recurrence',
      'Standardized manufactured product eliminates safety variability of conventional fecal transplant',
      'Robust efficacy with ~70% relative reduction in CDI recurrence vs. placebo',
    ],
    weaknesses: [
      'Requires completion of antibiotic course and 2-4 day washout before initiation',
      'Three consecutive daily doses of 4 capsules each with food restrictions may reduce compliance',
      'Long-term effects of microbiome modulation on health outcomes remain under study',
    ],
    source: 'Seres Therapeutics 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Rebyota',
    generic_name: 'fecal microbiota, live-jslm',
    company: 'Ferring Pharmaceuticals',
    indication: 'Clostridioides difficile Infection',
    indication_specifics: 'Prevention of recurrence of CDI in adults following antibacterial treatment for recurrent CDI',
    mechanism: 'Rectally administered broad consortium fecal microbiota preparation to restore gut microbial diversity',
    mechanism_category: 'microbiome_therapy',
    molecular_target: 'Gut microbiome diversity restoration',
    phase: 'Approved',
    primary_endpoint: 'Treatment success defined as absence of CDI recurrence through 8 weeks',
    key_data: 'PUNCH CD3 trial: 70.6% of Rebyota patients were CDI recurrence-free at 8 weeks vs. 57.5% for placebo; first FDA-approved fecal microbiota product (December 2022)',
    line_of_therapy: 'Post-antibiotic recurrence prevention',
    nct_ids: ['NCT03244644'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First FDA-approved fecal microbiota product establishing the regulatory pathway for the category',
      'Single rectal administration provides broad microbial diversity restoration in one visit',
      'Donor screening and manufacturing standardization improve safety over traditional FMT',
    ],
    weaknesses: [
      'Rectal administration requires healthcare professional and is less convenient than oral alternatives',
      'Derived from human donor stool retains theoretical risk of transmitting unknown pathogens',
      'Efficacy difference vs. placebo (~13%) is more modest compared to oral Vowst',
    ],
    source: 'Ferring Pharmaceuticals 2024',
    last_updated: '2025-01-15',
  },

  // ─── Hepatitis B ────────────────────────────────────────────────────────────
  {
    asset_name: 'Vemlidy',
    generic_name: 'tenofovir alafenamide',
    company: 'Gilead Sciences',
    indication: 'Hepatitis B',
    indication_specifics: 'Treatment of chronic hepatitis B virus infection in adults with compensated liver disease',
    mechanism: 'Nucleotide reverse transcriptase inhibitor (prodrug of tenofovir with improved renal/bone safety)',
    mechanism_category: 'nrti',
    molecular_target: 'HBV reverse transcriptase/polymerase',
    phase: 'Approved',
    primary_endpoint: 'HBV DNA <29 IU/mL at week 48',
    key_data: 'Phase 3 studies 0108/0110: TAF non-inferior to TDF with significantly less bone density decline and renal tubular biomarker changes; 73% virologic suppression in HBeAg-negative patients at week 48',
    line_of_therapy: '1L',
    nct_ids: ['NCT01940341', 'NCT01940471'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Improved renal and bone safety profile compared to tenofovir disoproxil fumarate (TDF)',
      'High barrier to resistance with no resistance detected through 6 years of treatment',
      'Once-daily oral tablet with no food restrictions and minimal drug interactions',
    ],
    weaknesses: [
      'Does not achieve functional cure (HBsAg loss) and requires indefinite therapy',
      'Premium pricing compared to generic TDF and entecavir alternatives',
      'Weight gain and lipid elevation noted as emerging safety signals with long-term use',
    ],
    source: 'Gilead Sciences 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Baraclude',
    generic_name: 'entecavir',
    company: 'Bristol-Myers Squibb',
    indication: 'Hepatitis B',
    indication_specifics: 'Treatment of chronic hepatitis B virus infection in adults and pediatric patients with evidence of active viral replication and liver disease',
    mechanism: 'Nucleoside analogue inhibiting HBV polymerase reverse transcriptase activity',
    mechanism_category: 'nrti',
    molecular_target: 'HBV polymerase/reverse transcriptase',
    phase: 'Approved',
    primary_endpoint: 'Histologic improvement and HBV DNA suppression at week 48',
    key_data: 'Superior to lamivudine in all Phase 3 endpoints; <1.2% resistance rate through 5 years in nucleoside-naive patients; extensive real-world evidence supporting long-term safety',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Extensive long-term safety data spanning over 15 years of clinical use',
      'Generic availability provides affordable access globally for chronic HBV management',
      'Very low resistance rate (<1.2% at 5 years) in treatment-naive patients',
    ],
    weaknesses: [
      'Requires indefinite therapy as functional cure remains elusive',
      'High resistance rates in lamivudine-experienced patients (~50% at 5 years)',
      'Potential carcinogenicity signal in animal studies at high exposures (black box warning)',
    ],
    source: 'Bristol-Myers Squibb 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Bepirovirsen',
    generic_name: 'bepirovirsen',
    company: 'GSK',
    indication: 'Hepatitis B',
    indication_specifics: 'Functional cure of chronic hepatitis B virus infection targeting HBsAg loss',
    mechanism: 'Antisense oligonucleotide targeting all HBV mRNA transcripts including cccDNA- and integrated DNA-derived species',
    mechanism_category: 'antisense_oligonucleotide',
    molecular_target: 'HBV mRNA (all transcripts)',
    phase: 'Phase 3',
    primary_endpoint: 'Sustained HBsAg loss and HBV DNA <LLOQ at 24 weeks after end of treatment',
    key_data: 'B-Clear Phase 2b: 9-10% of patients on bepirovirsen achieved sustained HBsAg and HBV DNA loss at follow-up; first ASO to demonstrate functional cure potential in a subset of CHB patients',
    line_of_therapy: 'Curative intent',
    nct_ids: ['NCT05630807', 'NCT05630820'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Potential to achieve functional cure of HBV, an unprecedented therapeutic goal',
      'Targets all HBV transcripts including those from integrated DNA, addressing major limitation of current therapies',
      'Biomarker-guided patient selection (baseline HBsAg levels) may enrich for responders',
    ],
    weaknesses: [
      'Modest overall functional cure rate (~10%) limits applicability to broader CHB population',
      'Weekly subcutaneous injections for 24 weeks represent a significant treatment burden',
      'ALT flares observed during treatment require careful monitoring and patient selection',
    ],
    source: 'GSK 2025',
    last_updated: '2025-01-15',
  },

  // ─── Iron Deficiency Anemia ─────────────────────────────────────────────────
  {
    asset_name: 'Injectafer',
    generic_name: 'ferric carboxymaltose',
    company: 'Vifor Pharma/CSL Behring',
    indication: 'Iron Deficiency Anemia',
    indication_specifics: 'Treatment of iron deficiency anemia in adults who are intolerant to or have had unsatisfactory response to oral iron',
    mechanism: 'IV iron replacement using carboxymaltose shell for controlled iron release',
    mechanism_category: 'iv_iron',
    molecular_target: 'Iron stores (ferritin, transferrin saturation)',
    phase: 'Approved',
    primary_endpoint: 'Hemoglobin increase >=2 g/dL from baseline at week 5',
    key_data: 'Multiple Phase 3 trials: >80% of patients achieved hemoglobin increase >=2 g/dL; two 750mg infusions (15 min each) given one week apart can correct total iron deficit',
    line_of_therapy: '2L (after oral iron failure)',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Rapid and complete iron repletion achievable in just two short infusions over one week',
      'Market-leading IV iron product with extensive clinical evidence across multiple etiologies',
      'Well-characterized safety profile with low rates of serious hypersensitivity',
    ],
    weaknesses: [
      'Risk of hypophosphatemia which can cause fatigue, bone pain, and osteomalacia with repeated dosing',
      'IV administration requires healthcare facility visit and monitoring',
      'Competition from Monoferric single-dose option challenges convenience positioning',
    ],
    source: 'CSL Behring 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Monoferric',
    generic_name: 'ferric derisomaltose',
    company: 'Pharmacosmos',
    indication: 'Iron Deficiency Anemia',
    indication_specifics: 'Treatment of iron deficiency anemia in adults who are intolerant to or have had unsatisfactory response to oral iron',
    mechanism: 'IV iron replacement using derisomaltose matrix allowing high single-dose administration',
    mechanism_category: 'iv_iron',
    molecular_target: 'Iron stores (ferritin, transferrin saturation)',
    phase: 'Approved',
    primary_endpoint: 'Change in hemoglobin from baseline to week 8',
    key_data: 'FERWON-IDA trial: non-inferior to ferric carboxymaltose for hemoglobin response; single high-dose infusion (up to 20 mg/kg, max 1000mg) in 20 minutes; significantly lower hypophosphatemia rates vs. FCM',
    line_of_therapy: '2L (after oral iron failure)',
    nct_ids: ['NCT02940886'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'True single-dose administration (up to 1000mg) enables complete iron repletion in one visit',
      'Significantly lower risk of hypophosphatemia compared to ferric carboxymaltose',
      'No maximum cumulative dose restriction allows flexible dosing for severe deficiency',
    ],
    weaknesses: [
      'Later market entrant competing against well-established Injectafer brand loyalty',
      'Infusion reactions including hypersensitivity can occur and require post-infusion observation',
      'Limited head-to-head data demonstrating clinical superiority over other IV iron formulations',
    ],
    source: 'Pharmacosmos 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Venofer',
    generic_name: 'iron sucrose',
    company: 'American Regent',
    indication: 'Iron Deficiency Anemia',
    indication_specifics: 'Treatment of iron deficiency anemia in CKD patients (dialysis and non-dialysis) and general IDA when oral iron is insufficient',
    mechanism: 'IV iron replacement using polynuclear iron(III)-hydroxide sucrose complex for direct iron delivery to transferrin and ferritin stores',
    mechanism_category: 'iron_replacement',
    molecular_target: 'Iron stores (transferrin/ferritin)',
    phase: 'Approved',
    primary_endpoint: 'Change in hemoglobin from baseline; ferritin and TSAT normalization',
    key_data: 'Extensive clinical experience since 2000; demonstrated hemoglobin increases of 1-2 g/dL over 4-6 weeks with standard dosing; most widely used IV iron in CKD-associated anemia globally',
    line_of_therapy: '2L (after oral iron failure or when oral iron insufficient)',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Longest track record among IV iron formulations with extensive safety data since 2000',
      'Well-established in both CKD and non-CKD iron deficiency anemia populations',
      'Lower cost than newer IV iron formulations; multiple generic versions available',
    ],
    weaknesses: [
      'Requires multiple infusion visits (typical cumulative dose 1000mg given as 200mg x 5 sessions)',
      'Older formulation lacks single high-dose convenience of Injectafer or Monoferric',
      'Free iron release risk with rapid administration; requires controlled infusion rate',
    ],
    source: 'FDA label; American Regent 2024',
    last_updated: '2025-01-15',
  },

  // ─── Immune Thrombocytopenia ────────────────────────────────────────────────
  {
    asset_name: 'Promacta',
    generic_name: 'eltrombopag',
    company: 'Novartis',
    indication: 'Immune Thrombocytopenia',
    indication_specifics: 'Treatment of chronic immune thrombocytopenia in adults and pediatric patients 1 year and older with insufficient response to prior therapy',
    mechanism: 'Small molecule thrombopoietin receptor agonist binding to the transmembrane domain of c-Mpl',
    mechanism_category: 'tpo_receptor_agonist',
    molecular_target: 'Thrombopoietin receptor (c-Mpl) transmembrane domain',
    phase: 'Approved',
    primary_endpoint: 'Platelet count >=50,000/uL during treatment period',
    key_data: 'RAISE trial: 79% of eltrombopag patients achieved platelet response vs. 28% placebo; oral once-daily administration; also approved for severe aplastic anemia and chronic HCV thrombocytopenia',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Oral daily tablet offers convenience advantage over subcutaneous romiplostim injections',
      'Broad label covering ITP, severe aplastic anemia, and HCV-associated thrombocytopenia',
      'Demonstrated durable platelet responses in long-term extension studies (>5 years)',
    ],
    weaknesses: [
      'Food and mineral supplement interactions (calcium, iron) require fasting restrictions complicating adherence',
      'Hepatotoxicity risk necessitates regular liver function monitoring',
      'Dose adjustments required for East Asian patients due to pharmacokinetic differences',
    ],
    source: 'Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Nplate',
    generic_name: 'romiplostim',
    company: 'Amgen',
    indication: 'Immune Thrombocytopenia',
    indication_specifics: 'Treatment of immune thrombocytopenia in adults and pediatric patients 1 year and older with insufficient response to prior therapy',
    mechanism: 'Fc-peptide fusion protein (peptibody) mimicking thrombopoietin to activate c-Mpl receptor',
    mechanism_category: 'tpo_receptor_agonist',
    molecular_target: 'Thrombopoietin receptor (c-Mpl) extracellular domain',
    phase: 'Approved',
    primary_endpoint: 'Durable platelet response (platelet count >=50,000/uL for >=6 of the last 8 weeks)',
    key_data: 'Pivotal trials: 56% durable platelet response in splenectomized and 79% in non-splenectomized ITP patients; long-term extension: >50% of patients achieved ITP remission off all treatments after sustained use',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Longest clinical experience among TPO-RAs with over 15 years of real-world safety data',
      'Evidence for treatment-free remission in a subset of patients after sustained use',
      'No food interaction restrictions and dose-proportional pharmacokinetics simplify management',
    ],
    weaknesses: [
      'Weekly subcutaneous injection burden compared to oral eltrombopag and avatrombopag',
      'Requires healthcare visits or self-injection training adding to patient burden',
      'Reticulin bone marrow fibrosis observed in some patients requiring periodic monitoring',
    ],
    source: 'Amgen 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Doptelet',
    generic_name: 'avatrombopag',
    company: 'Swedish Orphan Biovitrum (Sobi)',
    indication: 'Immune Thrombocytopenia',
    indication_specifics: 'Treatment of chronic immune thrombocytopenia in adults with insufficient response to prior therapy and thrombocytopenia in chronic liver disease patients undergoing procedures',
    mechanism: 'Small molecule thrombopoietin receptor agonist binding to the transmembrane domain of c-Mpl',
    mechanism_category: 'tpo_receptor_agonist',
    molecular_target: 'Thrombopoietin receptor (c-Mpl) transmembrane domain',
    phase: 'Approved',
    primary_endpoint: 'Platelet count >=50,000/uL on day 8 with no rescue therapy through day 7',
    key_data: 'Phase 3 ITP trial: 65% of avatrombopag patients achieved platelet response >=50,000/uL vs. 0% placebo; also approved for CLD-associated thrombocytopenia prior to procedures; can be taken with food',
    line_of_therapy: '2L+ (ITP) and pre-procedural (CLD)',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'No food restrictions (can be taken with meals) differentiating from eltrombopag fasting requirement',
      'Dual indication covering both chronic ITP and CLD thrombocytopenia before scheduled procedures',
      'No hepatotoxicity signal and no requirement for routine liver function monitoring',
    ],
    weaknesses: [
      'Later market entrant competing against well-entrenched Promacta and Nplate',
      'More limited long-term data compared to romiplostim and eltrombopag',
      'Thrombotic and thromboembolic events have been reported, particularly in CLD patients',
    ],
    source: 'Sobi 2024',
    last_updated: '2025-01-15',
  },

  // ─── Thrombotic Thrombocytopenic Purpura ────────────────────────────────────
  {
    asset_name: 'Cablivi',
    generic_name: 'caplacizumab',
    company: 'Sanofi',
    indication: 'Thrombotic Thrombocytopenic Purpura',
    indication_specifics: 'Treatment of acquired thrombotic thrombocytopenic purpura in adult patients, in combination with plasma exchange and immunosuppressive therapy',
    mechanism: 'Anti-von Willebrand factor nanobody blocking VWF-platelet interaction to prevent microvascular thrombosis',
    mechanism_category: 'anti_vwf_nanobody',
    molecular_target: 'von Willebrand factor (VWF) A1 domain',
    phase: 'Approved',
    primary_endpoint: 'Time to platelet count normalization',
    key_data: 'HERCULES trial: 55% faster platelet normalization vs. placebo (2.69 vs. 2.88 days); 74% reduction in composite endpoint of TTP-related death, recurrence, or major thromboembolic event',
    line_of_therapy: '1L (adjunctive to plasma exchange)',
    nct_ids: ['NCT02553317'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First targeted therapy for aTTP addressing the underlying VWF-platelet pathophysiology',
      'Significantly reduces TTP-related mortality, recurrence, and major thromboembolic events',
      'Rapid onset of action with subcutaneous self-administration enabling outpatient continuation',
    ],
    weaknesses: [
      'Increased bleeding risk requiring careful monitoring of patients on anticoagulants',
      'Must be used in combination with plasma exchange and immunosuppression, not as monotherapy',
      'High cost for an ultra-rare disease with limited payer negotiation leverage',
    ],
    source: 'Sanofi 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Rituximab',
    generic_name: 'rituximab',
    company: 'Roche',
    indication: 'Thrombotic Thrombocytopenic Purpura',
    indication_specifics: 'Off-label immunosuppressive therapy for acquired TTP to suppress ADAMTS13 autoantibody production',
    mechanism: 'Anti-CD20 chimeric monoclonal antibody depleting B lymphocytes to reduce autoantibody production',
    mechanism_category: 'anti_cd20',
    molecular_target: 'CD20 surface antigen on B lymphocytes',
    phase: 'Approved',
    primary_endpoint: 'ADAMTS13 activity normalization and clinical remission',
    key_data: 'Retrospective and cohort studies: rituximab used in ~60% of aTTP episodes; reduces relapse rate from ~40% to ~10% in first year; now used preemptively for refractory/relapsing cases',
    line_of_therapy: '1L-2L (off-label in TTP)',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Extensive real-world evidence supporting efficacy in aTTP with marked relapse reduction',
      'Targets the autoimmune pathophysiology by depleting ADAMTS13 autoantibody-producing B cells',
      'Biosimilar availability reduces cost and improves access globally',
    ],
    weaknesses: [
      'Off-label use in TTP means no TTP-specific dosing or safety data from pivotal registration trials',
      'Prolonged B-cell depletion increases infection risk including PML and HBV reactivation',
      'IV infusion requires healthcare facility and carries infusion reaction risk',
    ],
    source: 'Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Recombinant ADAMTS13',
    generic_name: 'TAK-755',
    company: 'Takeda',
    indication: 'Thrombotic Thrombocytopenic Purpura',
    indication_specifics: 'Enzyme replacement therapy for congenital TTP and potentially acquired TTP',
    mechanism: 'Recombinant ADAMTS13 metalloprotease replacing deficient or inhibited endogenous enzyme to cleave ultra-large VWF multimers',
    mechanism_category: 'enzyme_replacement',
    molecular_target: 'Ultra-large VWF multimers (substrate of ADAMTS13)',
    phase: 'Phase 3',
    primary_endpoint: 'Prevention of acute TTP episodes and maintenance of normal platelet counts in congenital TTP',
    key_data: 'Phase 3 in congenital TTP demonstrated normalization of ADAMTS13 activity and reduction in acute TTP episodes; potential to replace prophylactic plasma infusions in cTTP patients',
    line_of_therapy: 'Replacement therapy',
    nct_ids: ['NCT04683003'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Directly addresses the fundamental pathophysiology of ADAMTS13 deficiency in TTP',
      'Could eliminate need for prophylactic fresh frozen plasma infusions in congenital TTP',
      'First-in-class recombinant enzyme replacement with high specificity',
    ],
    weaknesses: [
      'Ultra-rare patient population (congenital TTP) limits commercial potential',
      'Neutralizing anti-drug antibodies may develop limiting long-term efficacy',
      'IV administration and potential need for frequent prophylactic dosing add treatment burden',
    ],
    source: 'Takeda 2025',
    last_updated: '2025-01-15',
  },

  // ─── Paroxysmal Nocturnal Hemoglobinuria ────────────────────────────────────
  {
    asset_name: 'Soliris',
    generic_name: 'eculizumab',
    company: 'Alexion Pharmaceuticals',
    indication: 'Paroxysmal Nocturnal Hemoglobinuria',
    indication_specifics: 'Treatment of PNH to reduce hemolysis and associated complications including thrombosis',
    mechanism: 'Humanized monoclonal antibody binding complement protein C5 to prevent formation of the membrane attack complex',
    mechanism_category: 'complement_inhibitor',
    molecular_target: 'Complement protein C5',
    phase: 'Approved',
    primary_endpoint: 'Reduction in intravascular hemolysis (LDH levels) and transfusion independence',
    key_data: 'TRIUMPH trial: 49% of eculizumab patients achieved transfusion independence vs. 0% placebo; 86% reduction in hemolysis (LDH); transformed PNH from a fatal disease to a manageable chronic condition',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Transformed PNH prognosis and established complement inhibition as the standard of care',
      'Extensive long-term safety and efficacy data spanning over 15 years of use',
      'Approved across multiple complement-mediated diseases (PNH, aHUS, gMG, NMOSD)',
    ],
    weaknesses: [
      'Every-2-week IV infusions impose significant treatment burden and healthcare utilization',
      'One of the most expensive drugs globally (~$500K/year) limiting access',
      'Residual extravascular hemolysis (C3-mediated) not addressed by terminal complement blockade',
    ],
    source: 'Alexion 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ultomiris',
    generic_name: 'ravulizumab',
    company: 'Alexion Pharmaceuticals',
    indication: 'Paroxysmal Nocturnal Hemoglobinuria',
    indication_specifics: 'Treatment of PNH in adults and pediatric patients 1 month and older',
    mechanism: 'Long-acting anti-C5 monoclonal antibody engineered for extended duration via pH-dependent recycling',
    mechanism_category: 'complement_inhibitor',
    molecular_target: 'Complement protein C5',
    phase: 'Approved',
    primary_endpoint: 'Non-inferiority to eculizumab in transfusion avoidance and LDH normalization',
    key_data: 'ALXN1210-PNH-301/302: non-inferior to eculizumab across all endpoints; every-8-week dosing (vs. every-2-week for Soliris); 73.6% achieved transfusion avoidance; complete LDH normalization in 53.6%',
    line_of_therapy: '1L',
    nct_ids: ['NCT02946463', 'NCT03056040'],
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Every-8-week dosing interval provides 4x less frequent infusions than eculizumab',
      'Engineered pH-dependent antibody recycling provides more consistent C5 coverage',
      'Rapid and comprehensive clinical development program enabled swift label expansion',
    ],
    weaknesses: [
      'Same ultra-premium pricing tier as Soliris with limited payer differentiation',
      'Residual extravascular hemolysis remains unaddressed by terminal complement inhibition',
      'IV infusion still required, disadvantaging against emerging oral and subcutaneous competitors',
    ],
    source: 'Alexion 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Iptacopan',
    generic_name: 'iptacopan',
    company: 'Novartis',
    indication: 'Paroxysmal Nocturnal Hemoglobinuria',
    indication_specifics: 'Treatment of PNH in adults who have residual anemia despite anti-C5 therapy or as monotherapy',
    mechanism: 'Oral factor B inhibitor blocking the alternative pathway of complement at the proximal level',
    mechanism_category: 'factor_b_inhibitor',
    molecular_target: 'Complement factor B',
    phase: 'Approved',
    primary_endpoint: 'Hemoglobin increase >=2 g/dL and hemoglobin >=12 g/dL at week 24 without transfusion',
    key_data: 'APPLY-PNH trial: 82% of patients on iptacopan achieved hemoglobin increase >=2 g/dL vs. 2% on anti-C5 alone; addresses both intravascular and extravascular hemolysis; first oral complement inhibitor for PNH',
    line_of_therapy: '2L (post anti-C5) and 1L monotherapy',
    nct_ids: ['NCT04558918'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First oral complement inhibitor for PNH eliminating infusion burden entirely',
      'Proximal complement blockade addresses both intravascular and extravascular hemolysis',
      'Superior hemoglobin improvement over anti-C5 therapy in patients with residual anemia',
    ],
    weaknesses: [
      'Twice-daily oral dosing requires consistent adherence compared to periodic infusions',
      'Proximal complement inhibition may carry theoretical risk of increased infections (especially encapsulated bacteria)',
      'Limited long-term safety data as a recently approved therapy',
    ],
    source: 'Novartis 2024',
    last_updated: '2025-01-15',
  },

  // ─── Beta-Thalassemia ──────────────────────────────────────────────────────
  {
    asset_name: 'Casgevy',
    generic_name: 'exagamglogene autotemcel',
    company: 'Vertex Pharmaceuticals/CRISPR Therapeutics',
    indication: 'Beta-Thalassemia',
    indication_specifics: 'Treatment of transfusion-dependent beta-thalassemia in patients 12 years and older for whom hematopoietic stem cell transplantation is appropriate',
    mechanism: 'Ex vivo CRISPR-Cas9 gene-edited autologous CD34+ hematopoietic stem cell therapy reactivating fetal hemoglobin production',
    mechanism_category: 'gene_therapy',
    molecular_target: 'BCL11A erythroid enhancer (CRISPR-mediated disruption)',
    phase: 'Approved',
    primary_endpoint: 'Transfusion independence for >=12 consecutive months',
    key_data: 'CLIMB-111 trial: 93.5% of evaluable TDT patients achieved transfusion independence for >=12 months; mean total hemoglobin >11 g/dL with fetal hemoglobin >40% of total; first CRISPR-based therapy approved',
    line_of_therapy: 'Curative intent',
    partner: 'CRISPR Therapeutics',
    nct_ids: ['NCT03655678'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First CRISPR-based gene therapy offering potential one-time curative treatment',
      'Over 93% transfusion independence rate demonstrating transformative clinical benefit',
      'Autologous approach eliminates graft-versus-host disease risk seen with allogeneic transplant',
    ],
    weaknesses: [
      'Requires myeloablative conditioning with busulfan carrying significant toxicity and infertility risk',
      'Extremely high list price ($2.2M) challenges payer adoption and global access',
      'Manufacturing complexity with patient-specific cell processing limits scalability',
    ],
    source: 'Vertex Pharmaceuticals 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lyfgenia',
    generic_name: 'lovotibeglogene autotemcel',
    company: 'bluebird bio',
    indication: 'Beta-Thalassemia',
    indication_specifics: 'Treatment of transfusion-dependent beta-thalassemia in patients aged 12 years and older for whom hematopoietic stem cell transplantation is appropriate',
    mechanism: 'Ex vivo lentiviral vector-mediated gene addition therapy inserting a modified beta-globin gene into autologous HSCs',
    mechanism_category: 'gene_therapy',
    molecular_target: 'Beta-globin gene locus (lentiviral gene addition)',
    phase: 'Approved',
    primary_endpoint: 'Transfusion independence for >=12 consecutive months',
    key_data: 'Phase 3 trials: 89% of evaluable patients with non-beta0/beta0 genotypes achieved transfusion independence; produces functional adult hemoglobin (HbAT87Q) restoring oxygen-carrying capacity',
    line_of_therapy: 'Curative intent',
    nct_ids: ['NCT02906202'],
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Produces functional adult hemoglobin (not fetal hemoglobin) more closely mimicking normal physiology',
      'Strong transfusion independence rates in non-beta0/beta0 genotype patients',
      'Autologous cell therapy avoids need for matched donor and GVHD risk',
    ],
    weaknesses: [
      'Black box warning for hematologic malignancy risk with insertional oncogenesis from lentiviral vector',
      'High cost ($3.1M) and bluebird bio financial instability raise access and durability concerns',
      'Lower efficacy in beta0/beta0 genotype patients who have the most severe disease',
    ],
    source: 'bluebird bio 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Reblozyl',
    generic_name: 'luspatercept',
    company: 'Bristol-Myers Squibb',
    indication: 'Beta-Thalassemia',
    indication_specifics: 'Treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions',
    mechanism: 'Modified activin receptor type IIB-Fc fusion protein trapping TGF-beta superfamily ligands to promote late-stage erythropoiesis',
    mechanism_category: 'activin_receptor_ligand_trap',
    molecular_target: 'TGF-beta superfamily ligands (GDF11, activin A/B)',
    phase: 'Approved',
    primary_endpoint: '>=33% reduction in transfusion burden over 12-week period versus baseline',
    key_data: 'BELIEVE trial: 21.4% of luspatercept patients achieved >=33% transfusion burden reduction vs. 4.5% placebo; reduces ineffective erythropoiesis characteristic of beta-thalassemia; subcutaneous every 3 weeks',
    line_of_therapy: '1L-2L for transfusion reduction',
    partner: 'Merck (ex-US)',
    nct_ids: ['NCT02604433'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First disease-modifying pharmacotherapy for beta-thalassemia reducing transfusion burden',
      'Non-curative but accessible alternative for patients who cannot undergo gene therapy',
      'Subcutaneous injection every 3 weeks offers manageable treatment burden',
    ],
    weaknesses: [
      'Modest transfusion reduction (~21% responders) falls short of curative gene therapy outcomes',
      'Does not eliminate need for transfusions in most patients, only reduces frequency',
      'Bone pain, arthralgia, and hypertension reported as common adverse events',
    ],
    source: 'Bristol-Myers Squibb 2024',
    last_updated: '2025-01-15',
  },

  // ─── Neovascular Age-Related Macular Degeneration ───────────────────────────
  {
    asset_name: 'Eylea',
    generic_name: 'aflibercept',
    company: 'Regeneron Pharmaceuticals',
    indication: 'Neovascular Age-Related Macular Degeneration',
    indication_specifics: 'Treatment of neovascular (wet) age-related macular degeneration',
    mechanism: 'Recombinant fusion protein acting as soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF',
    mechanism_category: 'anti_vegf',
    molecular_target: 'VEGF-A, VEGF-B, placental growth factor (PlGF)',
    phase: 'Approved',
    primary_endpoint: 'Proportion of patients maintaining vision (losing <15 ETDRS letters) at week 52',
    key_data: 'VIEW 1/2 trials: 95% of patients maintained vision at 52 weeks; non-inferior to monthly ranibizumab on every-8-week dosing; peak sales exceeding $9B globally making it the top-selling ophthalmic drug',
    line_of_therapy: '1L',
    nct_ids: ['NCT00509795', 'NCT00637377'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Well-established standard of care with over a decade of real-world evidence',
      'Broader VEGF binding spectrum (VEGF-A, VEGF-B, PlGF) compared to ranibizumab',
      'Every-8-week dosing in maintenance reduces injection burden vs. monthly alternatives',
    ],
    weaknesses: [
      'Biosimilar competition emerging with potential to significantly erode market share',
      'Every-8-week dosing interval still represents substantial treatment burden for elderly patients',
      'Loss of exclusivity and patent expiration looming in key markets',
    ],
    source: 'Regeneron 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Vabysmo',
    generic_name: 'faricimab',
    company: 'Roche',
    indication: 'Neovascular Age-Related Macular Degeneration',
    indication_specifics: 'Treatment of neovascular (wet) age-related macular degeneration',
    mechanism: 'Bispecific antibody targeting both VEGF-A and angiopoietin-2 to address vascular instability and inflammation',
    mechanism_category: 'anti_vegf_ang2',
    molecular_target: 'VEGF-A and angiopoietin-2 (Ang-2)',
    phase: 'Approved',
    primary_endpoint: 'Best-corrected visual acuity change from baseline at week 48',
    key_data: 'TENAYA/LUCERNE trials: non-inferior to aflibercept in vision gains; ~80% of patients maintained every-12-week or every-16-week dosing intervals at year 1; first bispecific antibody for retinal disease',
    line_of_therapy: '1L',
    nct_ids: ['NCT03823287', 'NCT03823300'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First bispecific antibody in ophthalmology targeting two complementary pathological pathways',
      'Up to 16-week dosing intervals significantly reduce injection frequency vs. standard aflibercept',
      'Dual VEGF-A and Ang-2 inhibition may provide superior vascular stabilization',
    ],
    weaknesses: [
      'Post-marketing reports of retinal vasculitis and occlusive retinal vasculitis have emerged',
      'Extended intervals may not be achievable in all patients, with some requiring more frequent dosing',
      'Premium pricing versus upcoming aflibercept biosimilars may limit cost-effectiveness',
    ],
    source: 'Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Eylea HD',
    generic_name: 'aflibercept 8 mg',
    company: 'Regeneron Pharmaceuticals',
    indication: 'Neovascular Age-Related Macular Degeneration',
    indication_specifics: 'Treatment of neovascular (wet) age-related macular degeneration with extended dosing intervals',
    mechanism: 'High-dose recombinant VEGF-trap fusion protein enabling extended durability through higher intraocular drug concentrations',
    mechanism_category: 'anti_vegf',
    molecular_target: 'VEGF-A, VEGF-B, placental growth factor (PlGF)',
    phase: 'Approved',
    primary_endpoint: 'Best-corrected visual acuity change from baseline at week 48',
    key_data: 'PULSAR trial: 8mg aflibercept every 12-16 weeks was non-inferior to 2mg aflibercept every 8 weeks; 78% of patients on 8mg maintained every-12-week or longer intervals at week 48; 4x higher dose extends durability',
    line_of_therapy: '1L',
    nct_ids: ['NCT04423718'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Up to 16-week dosing intervals with the established aflibercept molecule physicians trust',
      'Directly addresses the treatment burden that drives real-world undertreatment and vision loss',
      'Leverages extensive aflibercept safety database with well-characterized mechanism of action',
    ],
    weaknesses: [
      'Higher dose may increase risk of intraocular inflammation and injection-related adverse events',
      'Incremental innovation facing competitive bispecific and gene therapy approaches',
      'Premium pricing over standard Eylea while biosimilars enter the 2mg market at lower prices',
    ],
    source: 'Regeneron 2024',
    last_updated: '2025-01-15',
  },

  // ─── Diabetic Macular Edema ─────────────────────────────────────────────────
  {
    asset_name: 'Eylea',
    generic_name: 'aflibercept',
    company: 'Regeneron Pharmaceuticals',
    indication: 'Diabetic Macular Edema',
    indication_specifics: 'Treatment of diabetic macular edema',
    mechanism: 'Recombinant fusion protein acting as soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF',
    mechanism_category: 'anti_vegf',
    molecular_target: 'VEGF-A, VEGF-B, placental growth factor (PlGF)',
    phase: 'Approved',
    primary_endpoint: 'Best-corrected visual acuity gain from baseline at week 52',
    key_data: 'VIVID/VISTA trials: aflibercept 2mg every 8 weeks achieved +10.7 letter gains vs. +1.2 for laser at week 52; superior to laser in all visual and anatomic endpoints; standard of care in DME',
    line_of_therapy: '1L',
    nct_ids: ['NCT01331681', 'NCT01363440'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Robust vision gains of ~10 letters maintained through 148 weeks in long-term extension data',
      'Well-established standard of care with extensive real-world outcomes data in DME',
      'Every-8-week dosing after loading provides manageable treatment schedule',
    ],
    weaknesses: [
      'Chronic treatment burden with ongoing injections required indefinitely for most patients',
      'Biosimilar competition beginning to erode market share and pricing power',
      'Approximately 40% of DME patients show suboptimal response requiring alternative therapy',
    ],
    source: 'Regeneron 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Vabysmo',
    generic_name: 'faricimab',
    company: 'Roche',
    indication: 'Diabetic Macular Edema',
    indication_specifics: 'Treatment of diabetic macular edema',
    mechanism: 'Bispecific antibody targeting both VEGF-A and angiopoietin-2 to reduce vascular permeability and inflammation',
    mechanism_category: 'anti_vegf_ang2',
    molecular_target: 'VEGF-A and angiopoietin-2 (Ang-2)',
    phase: 'Approved',
    primary_endpoint: 'Best-corrected visual acuity change from baseline at week 48',
    key_data: 'YOSEMITE/RHINE trials: faricimab every 8-16 weeks was non-inferior to aflibercept every 8 weeks in BCVA gains; ~60% of patients achieved every-16-week dosing at year 1; robust central subfield thickness reductions',
    line_of_therapy: '1L',
    nct_ids: ['NCT03622580', 'NCT03622593'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Up to 16-week dosing intervals provide significant injection burden reduction in DME',
      'Dual pathway inhibition may benefit patients with inflammatory-driven DME component',
      'Strong anatomic outcomes with robust CST reductions supporting visual acuity gains',
    ],
    weaknesses: [
      'Rare but serious retinal vasculitis and occlusive retinal vasculitis events reported post-approval',
      'Not all patients achieve extended dosing, with some requiring every-4-week treatment',
      'Limited head-to-head data against anti-VEGF agents other than aflibercept 2mg',
    ],
    source: 'Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ozurdex',
    generic_name: 'dexamethasone intravitreal implant',
    company: 'AbbVie',
    indication: 'Diabetic Macular Edema',
    indication_specifics: 'Treatment of diabetic macular edema in adult patients who are pseudophakic or considered insufficiently responsive to non-corticosteroid therapy',
    mechanism: 'Biodegradable sustained-release intravitreal corticosteroid implant suppressing inflammation and vascular permeability',
    mechanism_category: 'corticosteroid_implant',
    molecular_target: 'Glucocorticoid receptor (broad anti-inflammatory)',
    phase: 'Approved',
    primary_endpoint: 'Best-corrected visual acuity improvement >=15 letters from baseline',
    key_data: 'MEAD trial: 22.2% of Ozurdex patients gained >=15 letters at 3 years vs. 12% sham; duration of effect ~4-6 months per implant; particularly effective in pseudophakic and vitrectomized eyes',
    line_of_therapy: '2L (after anti-VEGF) or 1L in pseudophakic patients',
    nct_ids: ['NCT00168337', 'NCT00168389'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Fewer injections per year (every 4-6 months) compared to monthly anti-VEGF regimens',
      'Effective in anti-VEGF insufficient responders and eyes with inflammatory DME component',
      'Biodegradable implant eliminates need for surgical removal',
    ],
    weaknesses: [
      'Cataract formation in nearly all phakic eyes (~68%) limits use to pseudophakic patients',
      'Intraocular pressure elevation requiring IOP-lowering drops in ~30% of patients',
      'More modest visual acuity gains compared to anti-VEGF agents in head-to-head comparisons',
    ],
    source: 'AbbVie 2024',
    last_updated: '2025-01-15',
  },
];
